Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

癌バイオマーカーの世界市場:タンパク質バイオマーカー、ジェネティックバイオマーカー

◆タイトル:Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020
◆商品コード:MAM-BT-3693
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年8月28日
◆ページ数:259
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、癌バイオマーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、産業動向、市場シェア分析、市場環境分析、がん種類別分析、製品種類別分析、技術別分析、用途別分析、市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:
• Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
• Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market

【レポートの目次】

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Stakeholders
1.3 Market Scope
1.4 Cancer Biomarkersmarkets Covered

2 Research Methodology (Page No. – 19)
2.1 Research Approach
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.4.1 Key Data From Secondary Sources
2.4.2 Key Data From Primary Sources
2.4.3 Key Industry Insights
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 28)

4 Premium Insights (Page No. – 32)

5 Market Overview (Page No. – 33)
5.1 Introduction
5.2 Market Segmentation
5.2.1 Cancer Biomarkers Market, By Type
5.2.2 Cancer Biomarkers Market, By Tumor Type
5.2.3 Cancer Biomarkers Market, By Profiling Technologies
5.2.4 Cancer Biomarkers Market, By Application
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Technological Advancements
5.3.1.2 Increasing Prevalence of Cancer
5.3.1.3 Enhanced Accuracy and Speed of Diagnosis
5.3.1.4 Increasing Use of Cancer Biomarkers in Drug Discovery and Development
5.3.1.5 Increasing Research on Cancer Biomarkers
5.3.1.6 Fda Support for Biomarker Development
5.3.2 Restraints
5.3.2.1 Poorly Suited Regulatory and Reimbursement Systems
5.3.2.2 High Capital Investment and Low Benefit-Cost Ratio
5.3.2.3 Technical Issues Related to Sample Collection and Storage
5.3.3 Opportunitites
5.3.3.1 Personalized Medicine
5.3.3.2 Companion Diagnostics
5.3.3.3 Emerging Economies
5.3.4 Challenges
5.3.4.1 Proving Clinical Validity and Utility of Biomarker-Based Tests Leading to Their Insufficient Acceptance

6 Industry Trends (Page No. – 49)
6.1 Introduction
6.2 Industry Trends
6.2.1 Increasing Use of Bimarkers for Developing Personalized Medicine
6.2.2 Advancements in Omics Technologies
6.3 Porter’s Five Forces Analysis
6.3.1 Threat From New Entrants
6.3.2 Threat From Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry
6.4 Strategic Benchmarking
6.4.1 New Product Launches and Product Enhancements

7 By Tumor Type (Page No. – 55)
7.1 Introduction
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Prostate Cancer
7.6 Cervical Cancer
7.7 Other Cancers

8 Cancer Biomarkers Market, By Type (Page No. – 61)
8.1 Introduction
8.2 Protein Biomarkers
8.3 Genetic Biomarkers
8.4 Other Cancer Biomarkers

9 By Profiling Technologies (Page No. – 64)
9.1 Introduction
9.2 Immunoassays
9.2.1 Elisa
9.2.2 Immunohistochemistry (IHC)
9.2.3 Flow Cytometry
9.3 Omics Technologies
9.3.1 Genomics
9.3.1.1 Next Generation Sequencing (NGS)
9.3.1.2 Microarrays
9.3.1.3 PCR (Polymer Chain Reaction)
9.3.2 Proteomics
9.3.2.1 Mass Spectrometry
9.3.2.1.1 Maldi Mass Spectrometry
9.3.2.1.2 Imaging Mass Spectrometry
9.3.2.2 2-D Gel Electrophoresis
9.3.2.3 Protein Microarray Technology
9.3.2.4 Antibody Array Technology
9.3.2.5 Peptide Array Technology
9.3.3 Other Omics Technologies
9.4 Cytogenetics
9.4.1 Ish (In Situ Hybridization)
9.4.2 Others
9.5 Imaging Technologies
9.5.1 Magnetic Resonance Imaging (MRI)
9.5.2 Positron Emission Tomography (PET)
9.5.3 Mammography
9.5.4 Computed Tomography (CT)
9.5.5 Ultrasound
9.6 Bioinformatics

10 By Application (Page No. – 88)
10.1 Introduction
10.2 Diagnostics
10.3 Drug Discovery and Development
10.4 Prognostics
10.5 Risk Assessment
10.6 Others

11 By Geographic Analysis (Page No. – 93)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (RoE)
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia-Pacific (RoAPAC)
11.5 Rest of the World (RoW)
11.5.1 Latin America
11.5.2 Middle East and Africa

12 Competitive Landscape (Page No. – 130)
12.1 Overview
12.2 Market Share Analysis, Global Cancer Biomarkers Market
12.3 Competitive Situation and Trends
12.3.1 New Product Launches
12.3.2 Expansions
12.3.3 Agreements, Partnerships, Collaborations, & Joint Ventures
12.3.4 Mergers & Acquisitions

13 Company Profiles (Page No. – 140)
13.1 Introduction
13.2 Abbott Laboratories
13.2.1 Business Overview
13.2.2 Products Offered
13.2.3 MnM View
13.2.4 Recent Developments
13.3 Affymetrix, Inc.
13.3.1 Business Overview
13.3.2 Products Offered
13.3.3 MnM View
13.3.4 Recent Developments
13.4 Illumina, Inc.
13.4.1 Business Overview
13.4.2 Products Offered
13.4.3 MnM View
13.4.4 Recent Developments
13.5 Qiagen N.V.
13.5.1 Business Overview
13.5.2 Qiagen N.V.: Company Snapshot
13.5.3 Products Offered
13.5.4 MnM View
13.5.5 Recent Developments
13.6 Roche Diagnostics Ltd.
13.6.1 Business Overview
13.6.2 Products Offered
13.6.3 MnM View
13.6.4 Recent Developments
13.7 Agilent Technologies, Inc.
13.7.1 Business Overview
13.7.2 Products Offered
13.7.3 MnM View
13.7.4 Recent Developments
13.8 Quest Diagnostics Inc.
13.8.1 Business Overview
13.8.2 Quest Diagnostics: Company Snapshot
13.8.3 Products Offered
13.8.4 Recent Developments
13.9 Merck & Co. Inc.
13.9.1 Business Overview
13.9.2 Products Offered
13.9.3 Recent Developments
13.10 Hologic, Inc.
13.10.1 Business Overview
13.10.2 Products Offered
13.10.3 Recent Developments
13.11 Becton, Dickinson and Company
13.11.1 Business Overview
13.11.2 Product Portfolio
13.11.3 Developmets

14 Appendix (Page No. – 167)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Available Customizations
14.4 Related Reports
14.5 Introducing RT: Real-Time Market Intelligence

List of Tables (191 Tables)

Table 1 Technological Advancments and Increasing Prevalence of Cancer to Fuel the Growth of Cancer Biomarkers Market
Table 2 Poorly Suited Regulatory and Reimbursement Systems are Hindering the Growth of Cancer Biomarkers Market
Table 3 Personalized Medicine and Emerging Markets Present an Array of Opportunitites for the Growth of Cancer Biomarkers Market
Table 4 Insufficient Acceptance, Proving Clinical Validity and Utility of Biomarker-Based Tests are A Major Challenge in the Cancer Biomarkers Market
Table 5 Global Cancer Biomarkers Market Size, By Tumor Type, 2013–2020 (USD Million)
Table 6 Global Breast Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 7 Global Lung Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 8 Global Colorectal Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 9 Global Prostate Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 10 Global Cervical Cancer Biomarkers Market Size, By Country/Region, 2013-2020 (USD Million)
Table 11 Global Cancer Biomarkers Market for Other Cancers, By Country/Region, 2013-2020 (USD Million)
Table 12 Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 13 Protein Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 14 Genetic Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 15 Other Cancer Biomarkers Market Size, By Country, 2013-2020 (USD Million)
Table 16 Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 17 Global Immunoassay Market Size, By Type, 2013-2020 (USD Million)
Table 18 Global Immunoassays Market Size, By Country/Region, 2013-2020 (USD Million)
Table 19 Global Elisa Market Size, By Country/Region, 2013-2020 (USD Million)
Table 20 Global IHC Market Size, By Country/Region, 2013-2020 (USD Million)
Table 21 Global Flow Cytometry Market, By Country/Region, 2013-2020 (USD Million)
Table 22 Global Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 23 Global Omics Technologies Market Size, By Country, 2013-2020 (USD Million)
Table 24 Global Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 25 Global Genomics Technologies Market Size, By Country/Region (USD Million)
Table 26 Global NGS Market Size, By Country/Region, 2013-2020 (USD Million)
Table 27 Global Microarray Market Size, By Country/Region, 2013-2020 (USD Million)
Table 28 Global PCR Market Size, By Country/Region, 2013-2020 (USD Million)
Table 29 Global Proteomics Market Size, By Country/Region, 2013-2020 (USD Million)
Table 30 Global Other Omics Technologies Market Size, By Country/Region, 2013-2020 (USD Million)
Table 31 Global Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 32 Global Cytogenetics Market Size, By Country, 2013-2020 (USD Million)
Table 33 Global Ish Market Size, By Country, 2013-2020 (USD Million)
Table 34 Global Other Cytogenetics Market Size, By Country, 2013-2020 (USD Million)
Table 35 Global Imaging Technologies Market Size, By Country, 2013-2020 (USD Million)
Table 36 Global Bioinfromatics Market Size, By Country, 2013-2020, USD Million
Table 37 Global Cancer Biomarkers Market Size, By Application
Table 38 Global Cancer Biomarkers Market for Diagnostics, By Country/Region, 2013-2020 (USD Million)
Table 39 Global Market for Drug Discovery and Development, By Country/Region, 2013-2020 (USD Million)
Table 40 Global Cancer Biomarkers Market for Prognostics, By Country/Region, 2013-2020 (USD Million)
Table 41 Global Cancer Biomarkers Market for Risk Assessment, By Country/Region, 2013-2020 (USD Million)
Table 42 Global Cancer Biomarkers Market for Other Applications, By Country/Region, 2013-2020 (USD Million)
Table 43 Global Cancer Biomarkers Market Size, By Region, 2013-2020 (USD Million)
Table 44 North America :Cancer Biomarkers Market Size, By Country, 2013-2020, (USD Million)
Table 45 North America: Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 46 North America: Market Size, By Type, 2013-2020, (USD Million)
Table 47 North America: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 48 North America: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 49 North America: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 50 North America: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 51 North America: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 52 North America: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 53 U.S.: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 54 U.S.: Market Size, By Type, 2013-2020, (USD Million)
Table 55 U.S.: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 56 U.S.: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 57 U.S.: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 58 U.S.: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 59 U.S.: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 60 U.S.: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 61 Canada: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 62 Canada: Market Size, By Type, 2013-2020, (USD Million)
Table 63 Canada: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 64 Canada: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 65 Canada: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 66 Canada: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 67 Canada: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 68 Canada: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 69 Europe: Market Size, By Country, 2013-2020, (USD Million)
Table 70 Europe: Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 71 Europe: Cancer Biomarkers Market Size, By Type, 2013-2020, (USD Million)
Table 72 Europe: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 73 Europe: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 74 Europe: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 75 Europe: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 76 North America: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 77 Europe: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 78 Germany: Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 79 Germany: Market Size, By Type, 2013-2020, (USD Million)
Table 80 Germany: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 81 Germany: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 82 Germany: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 83 Germany: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 84 Germany: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 85 Germany: Cancer Biomarkers Market Size, By Application, 2013-2020, (USD Million)
Table 86 U.K.: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020, (USD Million)
Table 87 U.K.: Market Size, By Type, 2013-2020, (USD Million)
Table 88 U.K.: Market Size, By Profiling Technologies, 2013-2020, (USD Million)
Table 89 U.K.: Omics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 90 U.K.: Genomics Technologies Market Size, By Type, 2013-2020, (USD Million)
Table 91 U.K.: Immunoassays Market Size, By Type, 2013-2020, (USD Million)
Table 92 U.K.: Cytogenetics Market Size, By Type, 2013-2020, (USD Million)
Table 93 U.K.: Cancer Biomarkers Market Size, By Application , 2013-2020, (USD Million)
Table 94 France: Cancer Biomarkers Market Size, By Tumor Type,2013-2020 (USD Million)
Table 95 France: Cancer Biomarkers Market Size, By Type,2013-2020 (USD Million)
Table 96 France: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 97 France: Omics Technologies Market Size, By Type ,2013-2020 (USD Million)
Table 98 France: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 99 France: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 100 France: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 101 France: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 102 Italy: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 103 Italy: Market Size, By Type,2013-2020 (USD Million)
Table 104 Italy: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 105 Italy: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 106 Italy: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 107 Italy: Immunoassays Market Size, By Type ,2013-2020 (USD Million)
Table 108 Italy: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 109 Italy: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 110 Spain: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 111 Spain: Market Size, By Type,2013-2020 (USD Million)
Table 112 Spain: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 113 Spain: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 114 Spain: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 115 Spain: Immunoassays Market Size, By Type ,2013-2020 (USD Million)
Table 116 Spain: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 117 Spain: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 118 RoE: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 119 RoE: Market Size, By Type,2013-2020 (USD Million)
Table 120 RoE: Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 121 RoE: Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 122 RoE: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 123 RoE: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 124 RoE: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 125 RoE: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 126 Asia-Pacific: Cancer Biomarkers Market Size, By Country,2013-2020 (USD Million)
Table 127 Asia-Pacific: Market Size, By Tumor Type,2013-2020 (USD Million)
Table 128 Asia-Pacific: Market Size, By Type,2013-2020 (USD Million)
Table 129 Asia-Pacific Cancer Biomarkers Market Size, By Profiling Technologies,2013-2020 (USD Million)
Table 130 Asia-Pacific Omics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 131 Asia-Pacific: Genomics Technologies Market Size, By Type,2013-2020 (USD Million)
Table 132 Asia-Pacific: Immunoassays Market Size, By Type,2013-2020 (USD Million)
Table 133 Asia-Pacific: Cytogenetics Market Size, By Type,2013-2020 (USD Million)
Table 134 Asia-Pacific: Cancer Biomarkers Market Size, By Application,2013-2020 (USD Million)
Table 135 Japan: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 136 Japan: Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 137 Japan: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 138 Japan: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 139 Japan: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 140 Japan: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 141 Japan: Cytogenetics Market Size, By Type , 2013-2020 (USD Million)
Table 142 Japan: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 143 China: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 144 China: Market Size, By Type, 2013-2020 (USD Million)
Table 145 China: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 146 China: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 147 China: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 148 China: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 149 China: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 150 China: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 151 India: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 152 India: Market Size, By Type, 2013-2020 (USD Million)
Table 153 India: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 154 India: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 155 India: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 156 India: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 157 India: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 158 India: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 159 RoAPAC: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 160 RoAPAC: Market Size, By Type, 2013-2020 (USD Million)
Table 161 RoAPAC: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 162 RoAPAC: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 163 RoAPAC: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 164 RoAPAC: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 165 RoAPAC: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 166 RoAPAC: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 167 RoW: Market Size, By Country, 2013-2020 (USD Million)
Table 168 RoW: Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 169 RoW: Cancer Biomarkers Market Size, By Type, 2013-2020 (USD Million)
Table 170 RoW: Cancer Biomarkers Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 171 RoW: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 172 RoW: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 173 RoW: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 174 RoW: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 175 RoW: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 176 Latin America: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 177 Latin America: Market Size, By Type, 2013-2020 (USD Million)
Table 178 Latin America: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 179 Latin America: Omics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 180 Latin America: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 181 Latin America: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 182 Latin America: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 183 Latin America: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)
Table 184 Middle East and Africa: Cancer Biomarkers Market Size, By Tumor Type, 2013-2020 (USD Million)
Table 185 Middle East and Africa: Market Size, By Type, 2013-2020 (USD Million)
Table 186 Middle East and Africa: Market Size, By Profiling Technologies, 2013-2020 (USD Million)
Table 187 Middle East and Africa: Omics Technologies Market Size, By Type , 2013-2020 (USD Million)
Table 188 Middle East and Africa: Genomics Technologies Market Size, By Type, 2013-2020 (USD Million)
Table 189 Middle East and Africa: Immunoassays Market Size, By Type, 2013-2020 (USD Million)
Table 190 Middle East and Africa: Cytogenetics Market Size, By Type, 2013-2020 (USD Million)
Table 191 Middle East and Africa: Cancer Biomarkers Market Size, By Application, 2013-2020 (USD Million)

List of Figures (38 Figureas)

Figure 1 Global Cancer Biomarkers Market
Figure 2 Research Methodology
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Cancer Biomarkers Market Size, By Technology, 2014 vs 2019 ($Million)
Figure 8 Global Cancer Biomarkers Market Size, By Accessories, 2014 vs 2019 ($Million)
Figure 9 Global Market Size, By End User, 2014 vs 2019 ($Million)
Figure 10 Market Share, 2013
Figure 11 Cancer Biomarkers Market, By Type
Figure 12 Cancer Biomarkers Market, By Tumor Type
Figure 13 Cancer Biomarkers Market, By Profiling Technologies
Figure 14 Cancer Biomarkers Market, By Application
Figure 15 Market: Drivers, Restraints, Opportunitites, and Challenges
Figure 16 Global Cancer Incidence , 2008–2025
Figure 17 Single- Use Or Disposable Products and One-Stop Shopping are Leading Trends in Market
Figure 18 Porter’s Five Forces Analysis (2014): Increasing Number of Local and Regional Players is Enhancing Competition in the Industry
Figure 19 Strategic Benchmarking: Pall, Sartorius and 3m Adopted Product Launches and Product Enhancement Strategies
Figure 20 Global Cancer Biomarkers Market, By Tumor Type
Figure 21 Cancer Biomarkers Market, By Application: Snapshot (2015-2020):
Figure 22 Geographic Snapshot (2015-2020)
Figure 23 Xx and Xx Hold High Growth Potential for Almost All Market Segments
Figure 24 North America Market Snapshot:
Figure 25 Germany is Major Market for Cancer Biomarkers Market in Europe, 2014
Figure 26 Asia Pacific Cancer Biomarkers Market Shanpshot: China and India are More Lucreative Markets
Figure 27 New Product Launches is the Key Growth Strategy Adopted By Majority of the Leading Players in the Market
Figure 28 Market Share Analysis, By Key Player, 2013
Figure 29 Battle for Market Share: New Product Launches Was the Key Strategy
Figure 30 Geographical Revenue Mix of Key Players in the Market
Figure 31 Abbott Laboratories: Company Snapshot
Figure 32 Affymetrix, Inc.: Company Snapshot
Figure 33 Illumina, Inc.: Company Snapshot
Figure 34 Roche Diagnostics: Company Snapshot
Figure 35 Agilent Technologies, Inc.: Company Snapshot
Figure 36 Merck & Co, Inc.: Company Snapshot
Figure 37 Hologic, Inc.: Company Snapshot
Figure 38 Becton, Dickinson and Company: Company Snapshot

【レポートのキーワード】

癌バイオマーカー、癌診断、タンパク質バイオマーカー、ジェネティックバイオマーカー、乳がん、肺がん、結腸直腸がん、前立腺ガン、子宮頸がん、バイオマーカー検査、免疫アッセイ、ELISA法、フローサイトメトリー、医療機器

★調査レポート[癌バイオマーカーの世界市場:タンパク質バイオマーカー、ジェネティックバイオマーカー] ( Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020 / MAM-BT-3693) 販売に関する免責事項
[癌バイオマーカーの世界市場:タンパク質バイオマーカー、ジェネティックバイオマーカー] ( Cancer Biomarkers Market by Tumor (Breast, Lung, Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020 / MAM-BT-3693) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆